MedTrace Logo

MMV390048 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants

NCT02281344 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2020-06-09

Study results available
· View outcomes & findings →

Summary

A single-centre, open-label, study using induced blood stage malaria infection to characterize the activity of MMV390048 against early Plasmodium falciparum blood stage infection.

Conditions

  • Malaria, Falciparum

Interventions

DRUG

MMV390048 20mg

Supplied as a powder to be prepared as a suspension for oral use

Sponsors & Collaborators

  • Q-Pharm Pty Limited

    collaborator INDUSTRY

  • Medicines for Malaria Venture

    lead OTHER

Principal Investigators

  • James McCarthy, Dr. · Q-Pharm Pty Limited

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2014-12-19
Completion
2014-12-19

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02281344 on ClinicalTrials.gov